Immunodeficiency Diseases
📧 Sign up to get email alerts when something new happens for Immunodeficiency Diseases.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-11-07Clinical Trial Update: Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases [Phase 3]
Phase 3 trial evaluating subcutaneous immunoglobulin with modified dosing regimens in patients with primary immunodeficiency disorders has c…
-
CLINICAL_TRIALS trial_result · 2023-10-23Clinical Trial Update: Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects [Phase 3]
Phase 3 trial evaluating HYQVIA in pediatric primary immunodeficiency diseases assessing efficacy, safety, tolerability, immunogenicity, and…
-
CLINICAL_TRIALS trial_result · 2023-01-11Clinical Trial Update: Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects [Phase 4]
Phase 4 post-authorization safety, tolerability, and immunogenicity evaluation of HyQvia in pediatric primary immunodeficiency disease patie…
-
CLINICAL_TRIALS trial_result · 2021-08-24Clinical Trial Update: Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders [Phase 3]
Phase 3 safety and efficacy study of a 10% intravenous immunoglobulin solution in subjects with primary immunodeficiency disorders has compl…
-
CLINICAL_TRIALS trial_result · 2021-08-24Clinical Trial Update: Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia) [Phase 2]
Phase 2 clinical trial update evaluating a 10% triple virally reduced intravenous immunoglobulin in patients with primary immunodeficiency (…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-05-05Clinical Trial Update: Immune Globulin Subcutaenous (Human), 20% [Phase 2, Phase 3]
Phase 2 and Phase 3 trial updates for Immune Globulin Subcutaneous (Human), 20% in primary immunodeficiency diseases have completed.
-
CLINICAL_TRIALS trial_result · 2021-05-05Clinical Trial Update: Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously [Phase 1, Phase 2]
A clinical trial aimed to determine the dose of recombinant human hyaluronidase needed to infuse a full dose of intravenous immunoglobulin s…
-
CLINICAL_TRIALS trial_result · 2017-08-25Clinical Trial Update: Study of Gut Microbiota in Primary Immune Deficiency, Possibly Associated With Inflammatory Bowel Disease
This clinical trial update reports the completion of a study on gut microbiota in people with primary immunodeficiency diseases, with possib…
-
CLINICAL_TRIALS trial_result · 2017-07-14Clinical Trial Update: Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency Diseases [Phase 3]
Phase 3 study evaluating the efficacy, safety and pharmacokinetics of Octagam 10% in primary immunodeficiency diseases was terminated; resul…
-
CLINICAL_TRIALS trial_result · 2017-04-24Clinical Trial Update: Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD [Phase 2, Phase 3]
Phase 2/3 trial update on tolerability and safety of IGI, 10% with rHuPH20 in primary immunodeficiency diseases; study completed with result…
-
CLINICAL_TRIALS trial_result · 2017-03-29Clinical Trial Update: Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases [Phase 3]
A Phase 3 bioequivalence study comparing Gammaplex 10% and Gammaplex 5% intravenous immunoglobulin in patients with primary immunodeficiency…
-
CLINICAL_TRIALS trial_result · 2017-03-16Clinical Trial Update: A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency Diseases [Phase 3]
Phase 3 trial of NewGam, a human immunoglobulin 10%, in primary immunodeficiency diseases has completed and results have been posted.
-
CLINICAL_TRIALS trial_result · 2017-02-15Clinical Trial Update: Phase 2/3 Study of IGSC, 20% in PIDD [Phase 2, Phase 3]
Phase 2/3 trial update for IGSC 20% in primary immunodeficiency diseases (PID) with completed status and results posted in 2017.
-
CLINICAL_TRIALS trial_result · 2016-05-26Clinical Trial Update: Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID [Phase 3]
Phase 3 trial assessing tolerability and safety of IGSC with rHuPH20 in primary immunodeficiency diseases completed with results posted in 2…
-
CLINICAL_TRIALS trial_result · 2015-12-03Clinical Trial Update: Gammagard Liquid and rHuPH20 in PID [Phase 3]
Phase 3 trial update for Gammagard Liquid with rHuPH20 in primary immunodeficiency diseases has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2014-01-10Clinical Trial Update: Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency [Phase 3]
A Phase 3 study of IVIG-SN for primary immunodeficiency has completed.
-
CLINICAL_TRIALS trial_result · 2012-08-23Clinical Trial Update: Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects [Phase 2, Phase 3]
A Phase 2/3 trial comparing intravenous and subcutaneous administration of 10% intravenous immunoglobulin for primary immunodeficiency disea…
-
CLINICAL_TRIALS research · 2012-07-17Clinical Trial Update: Evaluate Bacteriophage as a Useful Immunogen in Patients With Primary Immune Deficiency Diseases (PIDD) [NA]
Clinical trial investigating the use of bacteriophage as an immunogen in patients with primary immunodeficiency diseases.
-
CLINICAL_TRIALS trial_result · 2012-06-07Clinical Trial Update: Ig NextGen 10% in Patients With Primary Immune Deficiency (PID) [Phase 3]
A Phase 3 trial evaluating Ig NextGen 10% in patients with primary immunodeficiency diseases has completed.